Therapies Archives - The Boomer Esiason Foundation

Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor, and Ivacaftor Met Primary Endpoint of Improvement in Lung Function in People with Cystic Fibrosis

CF Community, CF News, Research, Therapies

March 20, 2019

SOURCE: VERTEX Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis Mean absolute improvement in ppFEV1 of 13.8 percentage points from baseline at week 4 in people with...

FDA Approves SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor)

by Emma Mueller

CF Community, CF News, Therapies

March 20, 2019

The U.S. Food and Drug Administration (FDA) approved SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) to treat cystic fibrosis (CF) in people ages 12 years and older who have two copies of the F508del mutation or one mutation that is responsive to SYMDEKO. SYMDEKO is Vertex’s third CF...

Corbus Pharma Receives $25 Million Development Award to Support Phase 2b Clinical Study of Lenabasum

by Emma Mueller

CF Community, CF News, Research, Therapies

March 20, 2019

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has received a Development Award for up to $25 million from the Cystic Fibrosis Foundation. The Development...

Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation

by Emma Mueller

Boomer Esiason Foundation, CF Community, CF News, Research, Therapies

March 20, 2019

SOURCE Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)-Phase 2 data showed mean absolute improvements in ppFEV1 of 9.7 and 12.0 percentage points...

PTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren

by Emma Mueller

CF Community, CF News, Research, Therapies

March 20, 2019

SOURCE: PRESS RELEASE VIA PTS THERAPEUTICSPTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren in Patients Living with Nonsense Mutation Cystic Fibrosis - ACT CF trial missed primary and secondary endpoints -- Company to host conference call today, March 2nd at 9:00 am...

Vertex Announces Planned Initiation of Phase 2 Studies Evaluating Next-Generation Correctors

by Emma Mueller

CF Community, CF News, Research, Therapies

March 20, 2019

FULL PRESS RELEASE HEREVertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis VX-440 to be evaluated as part of 4-week triple combination dosing with tezacaftor (VX-661) and ivacaftor;...

AbbVie and Galapagos to Co-Develop CF Therapies

by Emma Mueller

CF News, Therapies

March 19, 2019

Sep 24, 2013 SOURCE: ABBVIE NORTH CHICAGO, Ill. and MECHELEN, Belgium, Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis...

Cornerstone Therapeutics Inc. announced it is now actively marketing PERTZYE® in the US

by Emma Mueller

CF News, Therapies

March 19, 2019

SOURCE Cornerstone Therapeutics Initiates PERTZYE(R) (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis CARY, NC--(Marketwired - Jul 29, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today it is now actively marketing PERTZYE® (pancrelipase) in the U.S. for...

FDA Approves New Powder form of Novartis TOBI

by Emma Mueller

CF Community, CF News, Therapies

March 19, 2019

A dry powder form of the antibiotic TOBI - TOBI Podhaler (tobramycin inhalation powder) - used to treat lung infections caused by the bacteria Pseudomonas aeruginosa has been approved by the US Food and Drug Administration (FDA). People with CF ages six and older who have Pseudomonas aeruginosa and...

PTC Therapeutics Announces Promising Results from Phase 3 Trial of Ataluren

by Emma Mueller

CF News, Therapies

March 19, 2019

Source: Cystic Fibrosis Foundation PTC Therapeutics Inc. recently announced results from a Phase 3 clinical trial of ataluren, a potential oral drug aimed at treating the underlying cause of cystic fibrosis. The 48-week study tested ataluren in people with CF ages six and older who have what...

Therapies

Never miss an update. Subscribe to our emails!